Overview

A Phase 1 of Epetraborole Tablets

Status:
Recruiting
Trial end date:
2022-05-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study to evaluate the pharmacokinetics (PK), safety and tolerability of epetraborole tablets in adult subjects with normal renal function, subjects with various degrees of renal impairment, and subjects with end-stage renal disease (ESRD) receiving intermittent hemodialysis (IHD) therapy.
Phase:
Phase 1
Details
Lead Sponsor:
AN2 Therapeutics, Inc